UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Grows Holdings in Doximity, Inc. $DOCS

Key Points

• UBS AM increased its stake in Doximity, Inc. by 130.4%, owning 1,966,801 shares valued at approximately $114.1 million.
• Insider trading activity included sales by Directors Timothy S. Cabral and Kira Scherer Wampler, reducing their positions by 61.12% and 10.74% respectively.
• Doximity reported a 15.2% increase in revenue year-over-year and earnings per share of $0.36, surpassing analysts' expectations of $0.31.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 130.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,966,801 shares of the company's stock after purchasing an additional 1,113,076 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 1.05% of Doximity worth $114,133,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DOCS. SG Americas Securities LLC purchased a new position in Doximity during the first quarter valued at $65,702,000. Vanguard Group Inc. lifted its holdings in Doximity by 8.8% during the first quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company's stock valued at $707,646,000 after purchasing an additional 990,923 shares in the last quarter. Invesco Ltd. lifted its holdings in Doximity by 54.8% during the first quarter. Invesco Ltd. now owns 1,969,326 shares of the company's stock valued at $114,280,000 after purchasing an additional 696,923 shares in the last quarter. Nuveen LLC purchased a new position in shares of Doximity in the first quarter worth about $34,056,000. Finally, Pacer Advisors Inc. boosted its position in Doximity by 111.7% during the first quarter. Pacer Advisors Inc. now owns 629,042 shares of the company's stock worth $36,503,000 after acquiring an additional 331,910 shares during the last quarter. 87.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on DOCS shares. Bank of America boosted their price target on shares of Doximity from $55.00 to $62.00 and gave the stock a "neutral" rating in a research report on Wednesday, June 25th. Robert W. Baird boosted their price target on shares of Doximity from $75.00 to $80.00 and gave the stock an "outperform" rating in a research report on Thursday, September 11th. JPMorgan Chase & Co. lowered their price target on shares of Doximity from $63.00 to $60.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 27th. BTIG Research upgraded shares of Doximity from a "neutral" rating to a "buy" rating and set a $80.00 price target on the stock in a research report on Monday, June 2nd. Finally, Zacks Research lowered shares of Doximity from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eleven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $67.42.

Insiders Place Their Bets

In other news, Director Kira Scherer Wampler sold 2,000 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $57.09, for a total value of $114,180.00. Following the sale, the director directly owned 16,618 shares of the company's stock, valued at approximately $948,721.62. The trade was a 10.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Regina M. Benjamin sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the sale, the director directly owned 16,618 shares in the company, valued at $997,080. This trade represents a 37.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,000 shares of company stock valued at $2,281,880 over the last ninety days. Company insiders own 31.30% of the company's stock.

Doximity Trading Up 0.9%

DOCS stock traded up $0.69 during trading on Thursday, reaching $73.36. 302,198 shares of the stock were exchanged, compared to its average volume of 2,196,948. The business has a 50 day moving average price of $64.24 and a 200-day moving average price of $59.95. Doximity, Inc. has a 1 year low of $40.04 and a 1 year high of $85.21. The firm has a market capitalization of $13.74 billion, a price-to-earnings ratio of 73.33, a P/E/G ratio of 4.10 and a beta of 1.37.

Doximity (NASDAQ:DOCS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.36 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same quarter in the prior year, the firm earned $0.28 EPS. The firm's revenue was up 15.2% compared to the same quarter last year. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. On average, research analysts anticipate that Doximity, Inc. will post 0.99 EPS for the current year.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.